JNM CE/SAM (October 2017): PSMA Ligands for PET Imaging of Prostate Cancer

MOC Part II SAM Modules

JNM CE/SAM (October 2017): PSMA Ligands for PET Imaging of Prostate Cancer

JNM, October 2017, Volume 58, Number 110

Release Date: 10/1/2017
Expiration Date: 10/31/2020

SNMMI Members: Free
Non-Members: $69.00

Continuing Education Credit Information

ABNM SAM Credit
The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.

AMA-PRA (Physician)
The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Objectives
On successful completion of this activity, participants should be able to…
1. Recognize the current status of PSMA ligand PET imaging (clinical indications, diagnostic value, impact on treatment planning).
2. Apply PSMA PET/CT (patient preparation, image acquisition).
3. Interpret PSMA imaging

Target Audience
This article contains information of value to nuclear medicine physicians, oncologists, and urologists, as well as to nuclear medicine technologists

Authors
Sarah M. Schwarzenboeck1, Isabel Rauscher2, Christina Bluemel3, Wolfgang P. Fendler4,5, Steven P. Rowe6, Martin G. Pomper6, Ali Asfhar-Oromieh7,8, Ken Herrmann4,9, and Matthias Eiber2,4

1Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany; 2Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 3Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; 4Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; 5Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany; 6Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; 7Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; 8Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany; and 9Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Germany

Disclosure
Martin G. Pomper is a coinventor on a U.S. Patent covering 18F-DCFPyL, and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. Martin G. Pomper and Steven P. Rowe have received research support from Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.

Contact Information

For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.